Safety evaluation of the single-dose Ad26. COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial

Keyphrases

• Adverse Events 100%
• South Africa 100%
• Healthcare Workers 100%
• Safety Assessment 100%
• Ad26 100%
• S Vaccine 100%
• Implementation Trial 100%
• Vaccination 83%
• Safety Profile 33%
• Serious Adverse Events 33%
• Continued Use 33%
• Adverse Events of Special Interest 33%
• Hospitalization 16%
• Fever 16%
• Healthcare Professionals 16%
• Acetylcholinesterase 16%
• Headache 16%
• Vaccination Clinic 16%
• Revaccination 16%
• Clinical Trials 16%
• Self-reporting 16%
• Data Systems 16%
• National Database 16%
• Increasing Age 16%
• Licensure 16%
• Active Case Finding 16%
• Incidence Rate 16%
• Adverse Event Reporting 16%
• Infestation 16%
• Realist Evaluation 16%
• COVID-19 Infection 16%
• Reactogenicity 16%
• Text Messaging 16%
• Phase II Trial 16%
• Safety Data 16%
• Non-serious 16%
• Frequency Rate 16%
• Population Rates 16%
• Public Confidence 16%
• AE Events 16%
• Vaccine Registry 16%
• Injection Pain 16%
• Acceptable Safety 16%
• COVID-19 Breakthrough Infections 16%
• Thrombosis with Thrombocytopenia Syndrome 16%
• Immune System Disorder 16%
• Nervous System Diseases 16%
• Expected Rate 16%
• Single-arm Design 16%

Medicine and Dentistry

• Adverse Event 100%
• Single Drug Dose 100%
• Infection 27%
• COVID-19 18%
• Clinical Trial 9%
• Headache 9%
• Physical Disease by Body Function 9%
• Neurologic Disease 9%
• Arm 9%
• Thrombosis 9%
• Case Finding 9%
• Gene Linkage 9%
• Reactogenicity 9%
• Thrombocytopenia 9%
• Injection Site Pain 9%
• Immune Disorder 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Infection 27%
• Syndrome 18%
• Disease 9%
• Physical Disease by Body Function 9%
• Clinical Trial 9%
• Headache 9%
• Neurologic Disease 9%
• Thrombosis 9%
• Thrombocytopenia 9%
• Injection Site Pain 9%